Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Free Cash Flow (2019 - 2025)

Biodesix's Free Cash Flow history spans 7 years, with the latest figure at $692000.0 for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 114.02% year-over-year to $692000.0; the TTM value through Dec 2025 reached -$23.5 million, up 54.64%, while the annual FY2025 figure was -$23.5 million, 54.64% up from the prior year.
  • Free Cash Flow reached $692000.0 in Q4 2025 per BDSX's latest filing, up from -$8.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $809000.0 in Q2 2021 to a low of -$20.5 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$10.0 million, with a median of -$10.3 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: soared 118.23% in 2021, then crashed 1326.58% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$10.7 million in 2021, then dropped by 29.37% to -$13.9 million in 2022, then fell by 10.01% to -$15.3 million in 2023, then skyrocketed by 67.68% to -$4.9 million in 2024, then skyrocketed by 114.02% to $692000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Free Cash Flow are $692000.0 (Q4 2025), -$8.9 million (Q3 2025), and -$6.6 million (Q2 2025).